|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 2 | Prevalence of Autism Spectrum Disorder in China:A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 Years显示文摘This study aimed to obtain the first national estimate of the prevalence of autism spectrum disorder(ASD) in Chinese children.We targeted the population of 6 to 12-year-old children for this prevalence study by multistage convenient cluster sampling.The Modified Chinese Autism Spectrum Rating Scale was used for the screening process.Of the target population of 142,086 children,88.5%(n=125,806) participated in the study.A total of 363 children were confirmed as having ASD.The observed ASD prevalence rate was 0.29%(95% CI:0.26%-0.32%) for the overall population.After adjustment for response rates,the estimated number of ASD cases was867 in the target population sample,thereby achieving an estimated prevalence of 0.70%(95% CI:0.64%-0.74%).The prevalence was significantly higher in boys than in girls(0.95%;95% CI:0.87%-1.02% versus 0.30%;95%CI:0.26%-0.34%;P <0.001).Of the 363 confirmed ASD cases,43.3% were newly diagnosed,and most of those(90.4%) were attending regular schools,and 68.8% of the children with ASD had at least one neuropsychiatric comorbidity.Our findings provide reliable data on the estimated ASD prevalence and comorbidities in Chinese children. | Hao Zhou Xiu Xu Weili Yan Xiaobing Zou Lijie Wu Xuerong Luo Tingyu Li Yi Huang Hongyan Guan Xiang Chen Meng Mao Kun Xia Lan Zhang Erzhen Li Xiaoling Ge Lili Zhang Chunpei Li Xudong Zhang Yuanfeng Zhou Ding Ding Andy Shih Eric Fombonne Yi Zheng Jisheng Han Zhongsheng Sun Yong-hui Jiang Yi Wang LATENT-NHC Study Team | 2020 | Neuroscience Bulletin2020，36，9： | 158 |
| 3 | The Chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer显示文摘China is one of the countries with the highest incidence of gastric cancer.There are differences in epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selection between gastric cancer patients from the Eastern and Western countries.Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients.The Chinese Society of Clinical Oncology(CSCO)arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile,discuss,and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad.By referring to the opinions of industry experts,taking into account of regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted experts’consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes.This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis,comprehensive treatment,and follow-up visits for gastric cancer. | Feng-Hua Wang Lin Shen Jin Li Zhi-Wei Zhou Han Liang Xiao-Tian Zhang Lei Tang Yan Xin Jing Jin Yu-Jing Zhang Xiang-Lin Yuan Tian-Shu Liu Guo-Xin Li Qi Wu Hui-Mian Xu Jia-Fu Ji Yuan-Fang Li Xin Wang Shan Yu Hao Liu Wen-Long Guan Rui-Hua Xu | 2019 | Cancer Communications2019，39，1： | 127 |
| 4 | The Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021显示文摘There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western countries.The Chinese Society of Clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually.Taking into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China.The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis,treatment,follow-up,and screening of gastric cancer.Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from China and overseas for the past year,focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations.For the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant treatment.The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated.For the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided. | Feng-Hua Wang Xiao-Tian Zhang Yuan-Fang Li Lei Tang Xiu-Juan Qu Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Hong Qiu Chang Wang Miao-Zhen Qiu Mu-Yan Cai QiWu Hao Liu Wen-Long Guan Ai-Ping Zhou Yu-Jing Zhang Tian-Shu Liu Feng Bi Xiang-Lin Yuan Sheng-Xiang Rao Yan Xin Wei-Qi Sheng Hui-Mian Xu Guo-Xin Li Jia-Fu Ji Zhi-Wei Zhou Han Liang Yan-Qiao Zhang Jing Jin Lin Shen Jin Li Rui-Hua Xu | 2021 | Cancer Communications2021，41，8： | 97 |
| 5 | Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients显示文摘AIM To evaluate if the administration of anenteral diet supplemented with glutamine,arginine and ω-3-fatty acids modulatesinflammatory and immune responses aftersurgery.METHODS A prospective randomized double-blind, clinical trial was performed. Forty-eightpatients with gastrointestinal cancer wererandomized into two groups, one group wasgiven an isocaloric and isonitrogenous standarddiet and the other was fed with the supplementeddiet with glutamine, arginine and ωo-3-fattyacids. Feedings were started within 48 hoursafter operation, and continued until day 8. Allvariables were measured before operation andon postoperative day 1 and 8. Immune responseswere determined by phagocytosis ability,respiratory burst of polymorphonuclear cells,total lymphocytes lymphocyte subsets, nitricoxide, cytokines concentration, andinflammatory responses by plasma levels of C-reactive protein, prostaglandin E2 level.RESULTS Tolerance of both formula diets wasexcellent. There were siagnificant differences inthe immunological and inflammatory responsesbetween the two groups. In supplementedgroup, phagocytosis and respiratory burst aftersurgery was higher and C-reactive protein levelwas lower (P<0.01) than in the standard group.The supplemented group had higher levels ofnitric oxide, total Iymphocytes, T lymphocytes,T-helper cells, and NK cells. Postoperativelevels of IL-6 and TNF-α were lower in thesupplemented group ( P < 0.05).CONCLUSION It was clearly established in thistrial that early postoperative enteral feeding issafe in patients who have undergone majoroperations for gastrointestinal cancer.Supplementation of enteral nutrition withglutamine, arginine, and ω-3 fatty acidspositively modulated postsurgicalimmunosuppressive and inflammatoryresponses. | Guo Hao Wu Yan Wei Zhang Zhao Han Wu Department of General Surgery.zhongshan Hospital,ShangHai Medical University.ShangHai 200032.China | 2001 | World Journal of Gastroenterology2001，7，3： | 67 |
| 6 | Efficacy of cattle encephalon glycoside and ignotin in patients with acute cerebral infarction: a randomized, double-blind, parallel-group, placebo-controlled study显示文摘Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a safe and effective treatment for acute cerebral infarction patients,especially for moderate stroke patients.This study was approved by the Ethical Committee of Peking University Third Hospital,China(approval No.2013-068-2)on May 20,2013,and registered in the Chinese Clinical Trial Registry(registration No.ChiCTR1800017937). | Hui Zhang Chuan-Ling Li Feng Wan Su-Juan Wang Xiu-E Wei Yan-Lei Hao Hui-Lin Leng Jia-Min Li Zhong-Rui Yan Bao-Jun Wang Ren-Shi Xu Ting-Min Yu Li-Chun Zhou Dong-Sheng Fan | 2020 | Neural Regeneration Research2020，15，7： | 54 |
| 7 | Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies显示文摘Locoregional spread of abdominopelvic malignant tumors frequently results in peritoneal carcinomatosis(PC). The prognosis of PC patients treated by conventional systemic chemotherapy is poor, with a median survival of < 6 mo. However, over the past three decades, an integrated treatment strategy of cytoreductive surgery(CRS) + hyperthermic intraperitoneal chemotherapy(HIPEC) has been developed by the pioneering oncologists, with proved efficacy and safety in selected patients. Supported by several lines of clinical evidence from phases Ⅰ, Ⅱ and Ⅲ clinical trials, CRS + HIPEC has been regarded as the standard treatment for selected patients with PC in many established cancer centers worldwide. In China, an expert consensus on CRS + HIPEC has been reached by the leading surgical and medical oncologists, under the framework of the China Anti-Cancer Association. This expert consensus has summarized the progress in PC clinical studies and systematically evaluated the CRS + HIPEC procedures in China as well as across the world, so as to lay the foundation for formulating PC treatment guidelines specific to the national conditions of China. | Yan Li Yun-Feng Zhou Han Liang Hua-Qing Wang Ji-Hui Hao Zheng-Gang Zhu De-Seng Wan Lun-Xiu Qin Shu-Zhong Cui Jia-Fu Ji Hui-Mian Xu Shao-Zhong Wei Hong-Bin Xu Tao Suo Shu-Jun Yang Cong-Hua Xie Xiao-Jun Yang Guo-Liang Yang | 2016 | World Journal of Gastroenterology2016，22，30： | 58 |
| 8 | Milligan-Morgan hemorrhoidectomy with anal cushion suspension and partial internal sphincter resection for circumferential mixed hemorrhoids显示文摘AIM:To identify a more effective treatment protocol for circumferential mixed hemorrhoids.METHODS:A total of 192 patients with circumferential mixed hemorrhoids were randomized into the treatment group,where they underwent Milligan-Morgan hemorrhoidectomy with anal cushion suspension and partial internal sphincter resection,or the control group,where traditional external dissection and internal ligation were performed.Postoperative recovery and complications were monitored.RESULTS:The time to wound healing was 12.96 ± 2.25 d in the treatment group shorter than 19.58 ± 2.71 d in the control group.Slight pain rate was 58.3% in the treatment group higher than 22.9% in the control group;moderate pain rate was 33.3% in the treatment group lower than 56.3% in the control group severe pain rate was 8.4% in the treatment group lower than 20.8% in the control group.No edema rate was 70.8% in the treatment group higher than 43.8% in the control group;mild local edema rate was 26% in the treatment group lower than 39.6% in the control group obvious local edema was 3.03% in the treatment group lower than 16.7% in the control group.No stenosis rate was 85.4% in the treatment group higher than 63.5% in the control group;moderate stenosis rate was 14.6% in the treatment group Lower than 27.1% in the control group severe anal stenosis rate was 0% in the treatment group lower than 9.4% in the control group.CONCLUSION:Milligan-Morgan hemorrhoidectomy with anal cushion suspension and partial internal sphincter resection is the optimal treatment for circumferential mixed hemorrhoids and can be widely applied in clinical settings. | Ming Lu Guang-Ying Shi Guo-Qiang Wang Yan Wu Yang Liu Hao Wen | 2013 | World Journal of Gastroenterology2013，19，30： | 44 |
| 9 | Molecular and Biochemical Evidence for Phenylpropanoid Synthesis and Presence of Wall-linked Phenolics in Cotton Fibers显示文摘The mature cotton (Gossypium hirsutum L.) fiber is a single cell with a typically thickened secondary cell wall. The aim of this research was to use molecular, spectroscopic and chemical techniques to investigate the possible occurrence of previously overlooked accumulation of phenolics during secondary cell wall formation in cotton fibers. Relative quantitative reverse transcription-polymerase chain reaction analysis showed that GhCAD6 and GhCAD1 were predominantly expressed among seven gene homologs, only GhCAD6 was up-regulated during secondary wall formation in cotton fibers. Phylogenic analysis revealed that GhCAD6 belonged to Class I and was proposed to have a major role in monolignol biosynthesis, and GhCAD1 belonged to Class Ⅲ and was proposed to have a compensatory mechanism for monolignol biosynthesis. Amino acid sequence comparison showed that the cofactor binding sites of GhCADs were highly conserved with high similarity and identity to bona fide cinnamyl alcohol dehydrogenases. The substrate binding site of GhCAD1 is different from GhCAD6. This difference was confirmed by the different catalytic activities observed with the enzymes. Cell wall auto-fluorescence, Fourier transform infrared spectroscopy (FTIR), high-performance liquid chromatography (HPLC) and chemical analyses confirmed that phenolic compounds were bound to the cell walls of mature cotton fibers. Our findings may suggest a potential for genetic manipulation of cotton fiber properties, which are of central importance to agricultural, cotton processing and textile industries. | Ling Fan Wei-Jun Shi Wen-Ran Hu Xinn-Ynn Hao Dong-Mei Wang Hui Yuan Hong-Ying Yan | 2009 | Journal of Integrative Plant Biology2009，51，7： | 47 |
| 10 | The Genome of Artemisia annua Provides Insight into the Evolution of Asteraceae Family and Artemisinin Biosynthesis显示文摘Artemisia annua,通常已知的同样香甜的苦恼或 Qinghao,是到中国的一个灌木土著人并且长被用于药用的目的。A。annua 现在作为有势力抗疟药混合物的唯一的生来的来源全球性被栽培, artemisinin。这里,我们报导 A 的 1.74-gigabase 染色体的一个高质量的草稿集会。annua,高度异质接合,富于重复定序,并且包含 63 ? 226 编码蛋白质的基因,在定序的植物种类之中的最大的数字之一。我们发现了那,作为在 Asteraceae 的一些定序的染色体之一, A。annua 染色体包含对这大被子植物 clade 特定的很多基因。尤其是,扩大和编码涉及萜烯生合成的酶的基因的功能的多样化与 artemisinin biosynthetic 小径的进化一致。我们进一步由介绍那 A 的 transcriptome 揭示了。annua 发展了复杂 transcriptional 规章的网络位于 \O 下面 artemisinin 生合成。把转基因的 A 基于我们产生了的全面 genomic 和 transcriptomic 分析。artemisinin 高级的生产的 annua 线,它现在为大规模生产准备好了并且将从而帮助遇见增加 artemisinin 的全球需求的挑战。 | Qian Shen Lida Zhang Zhihua Liao Shengyue Wang Tingxiang Yan Pu Shi Meng Liu Xueqing Fu Qifang Pan Yuliang Wang Zongyou Lv Xu Lu Fangyuan Zhang Weimin Jiang Yanan Ma Minghui Chen Xiaolong Hao Ling Li Yueli Tang Gang Lv Yan Zhou Xiaofen Sun Peter E. Brodelius Jocelyn K.C. Rose Kexuan Tang | 2018 | Molecular Plant2018，11，6： | 47 |
| 11 | Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B显示文摘瞄准:与长期的肝炎 B (CHB ) 在病人学习在肝炎 B (HBV ) DNA 层次和肝组织学之间的关系并且决定肝炎 B e 的流行和特征抗原(HBeAg )negative 病人。方法:有 CHB 的 213 个病人的一个总数被学习,并且浆液 HBV DNA 层次被 COBAS Amplicor HBV 监视器测量测试。所有病人根据 HBeAg 地位被划分成二个组。在浆液 HBV DNA 层次和肝损坏(肝组织学和生物化学) 之间的关联被探索。结果:有比 105 copies/mL 高的浆液 HBV DNA 层次的 213 个病人,(83.6%) 178 是 HBeAg 积极,(16.4%) 35 是 HBeAg 否定。浆液 HBV DNA 层次没在否定的 HBeAg 或 HBeAg 被相关到肝疾病的年龄, CHB 的历史,组织学的等级和阶段积极病人。在 HBV DNA 和丙氨酸 aminotransferanse (中高音) 的浆液层次之间没有关联,在 HBeAg 积极病人的 aspartate aminotrans-ferase (著名计算机生产厂商) 。在 HBeAg 否定病人,当浆液 DNA 层次与中高音相关时,在 HBV DNA 和著名计算机生产厂商的浆液层次之间没有关联(r = 0.351, P = 0.042 ) 。肝疾病的等级(G) 与中高音和著名计算机生产厂商相关(P <
0.05, r = 0.205, 0.327 分别地) 在 HBeAg 积极病人。在 HBeAg 否定病人,关联在中高音,著名计算机生产厂商和 G 之间被显示出(P <
0.01,并且 r = 0.862, 0.802 分别地) 。 HBeAg 否定病人更老( 35 +/- 9 年对 30 +/- 9 年, P <
0.05 )并且有 HBV 感染的更长的历史( 8 +/- 4 年对 6 +/- 4 年, P <
0.05 )并且更低的 HBV DNA 比 HBeAg 积极病人铺平( 8.4 +/- 1.7 木头 HBV DNA 对 9.8 +/- 1.3 木头 HBV DNA , P <
0.001 )。在在二个组之间的两性比率,中高音和著名计算机生产厂商层次和肝组织学没有有效差量。结论:浆液 HBV DNA 水平没与 HBV DNA 在 CHB 病人被相关到肝疾病的组织学的等级或舞台超过 105 copies/mL。比作 HBeAg 积极病人, HBeAg 否定病人更老并且有更低的 HBV DNA 水平和更长的 HBV 感染历史。在在二个组之间的两性比率,中高音和著名计算机生产厂商层次和肝组织学没有有效差量。 | Jie Shao Lai Wei Hao Wang Yan Sun Lan-Fang Zhang Jing Li Jian-Qiang Dong | 2007 | World Journal of Gastroenterology2007，13，14： | 35 |
| 12 | Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis显示文摘Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. | Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng | 2019 | Neural Regeneration Research2019，14，3： | 35 |
| 13 | Hydroxysafflor yellow A improves learning and memory in a rat model of vascular dementia by increasing VEGF and NR1 in the hippocampus显示文摘Hydroxysafflor yellow A(HSYA) has angiogenesisregulating and neuro-protective effects, but its effects on vascular dementia(VaD) are unknown. In this study, 30 adult Sprague-Dawley rats were randomly allocated to five groups: normal, sham-operation, VaD alone(bilateral carotid artery occlusion), VaD plus saline(control), and VaD plus HSYA. One week after operation, the HSYA group received one daily tail-vein injection of 0.6 mg/100 g HSYA for two weeks. Five weeks after operation, the spatial memory of all five groups was evaluated by the water maze task, and synaptic plasticity in the hippocampus was assessed by the long-term potentiation(LTP) method. Vascular endothelial growth factor(VEGF) and N-methyl-Daspartic acid receptor 1(NR1) expression in the hippocampus was detected via Western blot. We found that, compared with the group with VaD alone, the group with HSYA had a reduced escape latency in the water maze(P <0.05), and the LTP at CA3-CA1 synapses in the hippocampus was enhanced(P <0.05). Western blot in the late-phase VaD group showed slight up-regulation of VEGF and downregulation of NR1 in the hippocampus, while HSYA significantly up-regulated both VEGF and NR1. Theseresults suggested that HSYA promotes angiogenesis and increases synaptic plasticity, thus improving spatial learning and memory in the rat model of VaD. | Nan Zhang Mengya Xing Yiyi Wang Hao Liang Zhuo Yang Fudong Shi Yan Cheng | 2014 | Neuroscience Bulletin2014，30，3： | 30 |
| 14 | Outbreak of Dengue Fever in Central China,2013显示文摘In 2013,the first dengue fever(DF) outbreak in central China was reported in the central of Henan province,northern temperate regions,although they have been sequentially recorded in Southern China.106 suspected DF cases were reported and 73 patients were confirmed dengue virus type 3(DEN-3) infections.62/392(15.8%) local health persons showed DEN antibodies positive.To this day Henan is the northernmost province in China which has been reported about outbreak of DF and what is important is that it warns us the endemic range of DF has been expanded geographically in China. | HUANG Xue Yong MA Hong Xia WANG Hai Feng DU Yan Hua SU Jia LI Xing Le TANG Xiao Yan MA Hong Peng ZU Bing Can ZHANG Qiao Hong CHEN Hao Min XU Bian Li | 2014 | Biomedical and Environmental Sciences2014，27，11： | 30 |
| 15 | An emerging hemorrhagic fever in China caused by a novel bunyavirus SFTSV显示文摘Severe fever with thrombocytopenia syndrome(SFTS) is an emerging hemorrhagic fever in rural areas of China and is caused by a new bunyavirus,SFTSV,named after the disease.The transmission vectors and animal hosts of SFTSV are unclear.Ticks are the most likely transmission vectors and domestic animals,including goats,dogs,and cattle,are potential amplifying hosts of SFTSV.The clinical symptoms of SFTS are nonspecific,but major symptoms include fever,gastrointestinal symptoms,myalgia,dizziness,joint pain,chills,and regional lymphadenopathy.The most common abnormalities in laboratory test results are thrombocytopenia(95%),leukocytopenia(86%),and elevated levels of serum alanine aminotransferase,aspartate aminotransferase,creatine kinase,and lactate dehydrogenase.The fatality rate for SFTS is 12% on average,and the annual incidence of the disease is approximately five per 100000 of the rural population. | ZHANG XiaoShuang LIU Yan ZHAO Li LI Bing YU Hao WEN HongLing YU Xue-Jie | 2013 | Science China(Life Sciences)2013，56，8： | 28 |
| 16 | Comparison of unipedicular and bipedicular percutaneouskyphoplasty for treating osteoporotic vertebral compression fractures:a meta-analysis显示文摘 | Li Lian-hua Sun Tian-sheng Liu Zhi Zhang Jian-zheng Zhang Yan Cai Yan-hong Wang Hao | 2013 | Chinese Medical Journal2013，，20： | 26 |
| 17 | Altered trends in carbon uptake in China’s terrestrial ecosystems under the enhanced summer monsoon and warming hiatus显示文摘The carbon budgets in terrestrial ecosystems in China are strongly coupled with climate changes.Over the past decade,China has experienced dramatic climate changes characterized by enhanced summer monsoon and decelerated warming.However,the changes in the trends of terrestrial net ecosystem production(NEP)in China under climate changes are not well documented.Here,we used three ecosystem models to simulate the spatiotemporal variations in China's NEP during 1982–2010 and quantify the contribution of the strengthened summer monsoon and warming hiatus to the NEP variations in four distinct climatic regions of the country.Our results revealed a decadal-scale shift in NEP from a downtrend of–5.95 Tg C/yr^2(reduced sink)during 1982–2000 to an uptrend of 14.22 Tg C/yr^2(enhanced sink)during 2000–10.This shift was essentially induced by the strengthened summer monsoon,which stimulated carbon uptake,and the warming hiatus,which lessened the decrease in the NEP trend.Compared to the contribution of 56.3%by the climate effect,atmospheric CO2 concentration and nitrogen deposition had relatively small contributions(8.6 and 11.3%,respectively)to the shift.In conclusion,within the context of the global-warming hiatus,the strengthening of the summer monsoon is a critical climate factor that enhances carbon uptake in China due to the asymmetric response of photosynthesis and respiration.Our study not only revealed the shift in ecosystem carbon sequestration in China in recent decades,but also provides some insight for understanding ecosystem carbon dynamics in other monsoonal areas. | Honglin He Shaoqiang Wang Li Zhang Junbang Wang Xiaoli Ren Lei Zhou Shilong Piao Hao Yan Weimin Ju Fengxue Gu Shiyong Yu Yuanhe Yang Miaomiao Wang Zhongen Niu Rcmg Ge Huimin Yan Mei Huang Guoyi Zhou Yongfei Bai Zongqiang Xie Zhiyao Tang Bingfang Wu Leiming Zhang Nianpeng He Qiufeng Wang Guirui Yu | 2019 | National Science Review2019，6，3： | 24 |
| 18 | Relationship between hs-CRP, proMMP-1, TIMP-1 and coronary plaque morphology: intravascular ultrasound study显示文摘Background Rupture of unstable plaque with subsequent thrombus formation is the common pathophy- siological substrate of the acute coronary syndrome (ACS). It is of potential significance to explore the blood indexes predicting plaque characteristics. Little studies have focused on this field. Therefore we investigated the relationship between hypersensitive C-reactive protein (hs-CRP), pro-matrix metalloproteinase-1 (proMMP-1), tissue inhibitors of matrix metalloproteinase-1 (TIMP-1) and coronary plaque morphology. Methods Intravascular ultrasound (IVUS) examination was done in 152 patients with confirmed coronary heart disease before percutaneous coronary intervention from February 2003 to July 2005. Plasma samples of arterial blood were collected prior to the procedure. The level of hs-CRP, proMMP-1 and TIMP-1 were respectively measured by enzyme-linked immunosorbent assay (ELISA). Results Unstable and ruptured plaque were found more frequently in patients with acute myocardial infarction and unstable angina. External elastic membrane cross-sectional area (EEM CSA), plaque area, lipid pool area and plaque burden were significantly larger in ruptured and unstable plaque group. Positive remolding, thinner fabric-cap, smaller minimal lumen cross-sectional area (MLA), dissection and thrombus were significantly more frequent in ruptured and unstable plaque group. The levels of plasma hs-CRP, proMMP-1 and TIMP-1 were higher in ruptured plaque group. hs-CRP>8.94 mg/L was used to predict ruptured plaque with a ROC curve area of 0.76 [95% confidence interval (CI), 67.0%-85.8%], sensitivity of 71.8%, specificity of 77.0% and accuracy of 69.2% (P<0.01), similarly for proMMP-1>0.12 ng/ml with a ROC curve area of 0.69 [95% CI, 58.2%-80.2%], sensitivity of 69.2%, specificity of 75.2% and accuracy of 66.2% (P<0.01), and TIMP-1>83.45 ng/ml with a ROC curve area of 0.67 [95% CI, 56.2%-78.3%], sensitivity of 66.7%, specificity of 61.9% and accuracy of 66.2% (P<0.01). Conclusion The plaque characteristics correlate with the clinical presentation. The elevation of hs-CRP, proMMP-1 and TIMP-1 are related to the plaque instability and rupture. | ZHANG Xing-wei GE Jun-bo YANG Jian-min GE Lei WANG Ning-fu GAO Yan LI Pei-zhang PAN Hao TONG Guo-xin ZHOU Liang YE Xian-hua XU Jian | 2006 | Chinese Medical Journal2006，，20： | 23 |
| 19 | Biomechanical effects of bone cement volume on the endplates of augmented vertebral body: a three-dimensional finite element analysis显示文摘 | Yan Liang Chang Zhen Xu Zhengwei Liu Tuanjiang He Baorong Hao Dingjun | 2014 | Chinese Medical Journal2014，，1： | 23 |
| 20 | Somatosensory neuron types identified by high-coverage single-cell RNA-sequencing and functional heterogeneity显示文摘感觉神经原被不同发信号的网络和接受特征区分。因此,感觉神经原类型能被连接基于 transcriptome 的神经原与感觉显型打字定义。这里,我们分类老鼠的 somatosensory 神经原由高范围的单个房间的定序 RNA 的背面的根中心(DRG )(10 950 ±1 218 基因每神经原) 并且神经原基于尺寸的层次聚类。而且,对皮肤的刺激作出回应的单个 DRG 神经原被记录用一在里面 vivo 整个房间的补丁夹钳技术并且由神经原类型分类基因标记。小直径 DRG 神经原被分类进低阀值的 mechanoreceptor 的一种类型和 mechanoheat nociceptors (MHN ) 的五种类型。每 MHN 类型进一步被分成二种子类型。大 DRG 神经原被分成四种类型,包括表示联系 BAI1 的蛋白质 2-like 的 neurexophilin 1 快车 MHN 和机械 nociceptors (MN ) 1 (Baiap2l1 ) 。表示 trafficking 蛋白质粒子建筑群 3-like 和 Baiap2l1 显著的 MN 的 Mechanoreceptors 各被细分进二种子类型。这些结果为编目 somatosensory 神经原和他们的 transcriptome 数据库提供一个新系统。 | Chang-Lin Li Kai-Cheng Li Dan Wu Yan Chen Hao Luo Jing-Rong Zhao Sa-Shuang Wang Ming-Ming Sun Ying-Jin Lu Yan-Qing Zhong Xu-Ye Hu Rui Hou Bei-Bei Zhou Lan Bao Hua-Sheng Xiao Xu Zhang | 2016 | Cell Research2016，26，1： | 21 |
您所在的机构暂未开通此部分的功能，请联系管理员